Links on this page relate to essential thrombocythemia.
General MPN information is at the main MPN guidelines and articles page.
Essential thrombocythemia (ET) specific information
- Essential thrombocythemia: 2024 update on diagnosis, risk stratification and management, AJH, 2024
- Site specific venous thrombosis in ET: impact on subsequent vascular events and survival, ‘Journal of thrombosis and haemostasis’, 2022
- Essential thrombocythemia: challenges in clinical practice and future prospects, Blood 2023
- Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk stratification and management, USA
- Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet, 2021
- MPL-mutated essential thrombocythemia: a morphologic reappraisal, Blood Cancer Journal, 2018
- Pro106Leu MPL mutation is associated with thrombocytosis and a low risk of thrombosis, splenomegaly and marrow fibrosis, Platelets, 2022
- Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients, AJH, Research article, 2014
